Aug. 18. 2025
Osaka, Japan – August 15, 2025 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Motohiko Kimura) received approvals by the Ministry of Health, Labour and Welfare for Five generic drugs with 11 strengths. The three compounds marked with an asterisk below are approved for the first time as generics.
The list of approved products
1. DAPAGLIFLOZIN Tablets, OD Tablets
| Generic name | Dapagliflozin* |
|---|---|
| Strengths | Tablets: 5mg, 10mg OD Tablets: 5mg, 10mg |
| Brand products | forxiga tablets 5mg, 10mg |
2. LACOSAMIDE Tablets, DS
| Generic name | Lacosamide* |
|---|---|
| Strengths | Tablets: 50mg, 100mg DS: 10% |
| Brand products | VIMPAT® TABLETS 50mg, 100mg VIMPAT® DRY SYRUP 10% |
3. EFINACONAZOLE Solution
| Generic name | Efinaconazole |
|---|---|
| Strengths | Solution: 10% |
| Brand products | CLENAFIN® Topical Solution 10% |
4. NILOTINIB Capsules
| Generic name | Nilotinib* |
|---|---|
| Strengths | Capsules: 150mg, 200mg |
| Brand products | Tasigna® Capsules 150mg, 200mg |
5. ABIRATERONE ACETATE Tablets
| Generic name | Abiraterone Acetate |
|---|---|
| Strengths | Tablets: 250mg |
| Brand products | ZYTIGA® tablets 250mg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.